FMISO-based Adaptive Radiotherapy for Head and Neck Cancer

Inclusion Criteria: * Pathologically proven new diagnosis of oropharyngeal p16 negative, or laryngeal, hypopharyngeal, oral cavity (independent of p16) squamous cell carcinoma of clinical stage III, IV confined to head and neck area * Evaluable tumor burden assessed by computed tomography scan or magnetic resonance imaging, based on RECIST (Response Evaluation Criteria in Solid Tumours) version 1.1 * Eligibiity for definitive chemoradiation or hyperfractionated accelerated radiotherapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate kidney and liver function Exclusion Criteria: * Prior surgical treatment - any surgery of primary tumor or involved nodes or prior surgical debulking apart from surgery with diagnostic intention (e.g. open biopsy if necessary) * Prior systemic therapy, targeted therapy, radiotherapy treatment for head and neck cancer * Cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or unknown primary head and neck cancer * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis or any distant metastasis * Known active Hepatitis B or C * History of Human Immunodeficiency Virus (HIV) * History of a diagnosed and/or treated hematologic or primary solid tumor malignancy, unless in remission for at least 5 years prior to randomization * Previous allogeneic tissue/solid organ transplant * Active infection requiring systemic therapy